Diagnosis model of platelet 102 gene for ovarian cancer, construction method and application

Abstract

The invention belongs to the technical field of biomarkers, and discloses a platelet 102 gene diagnosis model for ovarian cancer as well as a construction method and application thereof, and the construction method of the platelet 102 gene diagnosis model for ovarian cancer comprises the following steps: collecting, separating and extracting a platelet sample; carrying out platelet RNA extraction and quality control; carrying out RNA-seq library establishment and sequencing on the platelet samples; platelet RNA-seq original data processing is carried out; and carrying out feature selection and model construction. Compared with CA125, the diagnosis performance of the diagnosis model TEPOC based on the platelet 102 gene constructed by the invention is improved to different degrees in an internal verification set (DC) and three external verification sets (VC1, VC2 and VC3), and the combination of TEPOC and CA125 can further improve the diagnosis performance of ovarian cancer. In addition, the present invention (TEPOC) is also superior to CA125 in distinguishing endometriosis from ovarian cancer and identifying the manifestations of patients with border, early and non-epithelial ovarian cancer.

Description

Technical field [0001] The invention is a biomarker technology field, especially involving a diagnostic model, construction method and application for platelet 102 genes for ovarian cancer. Background technique [0002] At present, the CA125 is currently the most widely used platelet 102 gene for diagnostic symbols for ovarian cancer, but its clinical application has many limitations: [0003] (1) The overall specific specificity is not high [0004] Bndomical diseases such as women's physiological period, pregnancy status, or endometriosis, pelvic inflammatory disease and other benign diseases may also lead to increased CA125. [0005] (2) Poor sensitivity to special types of ovarian cancer [0006] Although 80 % of patients with epithelial ovarian cancer are often increased with CA125, CA125 of patients with early and non -epithelial ovarian malignant tumors is often negative. [0007] Due to the above -mentioned limitations, the latest analysis results of UKCTOCs, the largest ...

AI Technical Summary

Problems solved by technology

[0005] (2) Poor sensitivity to specific types of ovarian cancer

[0009] (1) The existing CA125-based platelet 102 gene diagnostic markers for ovarian cancer have low overall specificity and poor sensitivity for special types of ovarian cancer

[0010] (2) Serum tumor marker CA125 screening alone or combined with transvaginal ultrasound cannot effectively reduce the mortality of ovarian cancer patients

[0011] The difficulty in solving the above problems and defects is: currently there is no clinically feasible platelet 102 gene with both sensitivity and specificity as a diagnostic marker for ovarian cancer

Images